Exosite inhibition of A Disintegrin And Metalloproteinase with Thrombospondin motif (ADAMTS)-5 by a glycoconjugated arylsulfonamide
Santamaria, S.; Cuffaro, D.; Nuti, E.; Ciccone, L.; Tuccinardi, T.; Liva, F.; D'Andrea, F.; de Groot, R.; Rossello, A.; Ahnstroem, J.
Show abstract
ADAMTS-5 is a major protease involved in the turnover of proteoglycans such as aggrecan and versican. Its aggrecanase activity has been directly linked to the etiology of osteoarthritis (OA), identifying ADAMTS-5 as a pharmaceutical target for OA treatment. However, most existing ADAMTS-5 inhibitors target its active site and therefore suffer from poor selectivity. Here, using a novel approach, we have designed a new class of sugar-based arylsulfonamide inhibitors, which are selective for ADAMTS-5 through binding to a previously unknown substrate-binding site (exosite). Docking calculations combined with molecular dynamics simulations demonstrated that our lead compound is a cross-domain inhibitor that targets the interface of the metalloproteinase and disintegrin-like domains. Targeted mutagenesis identified disintegrin-like domain residues K532 and K533 as an exosite which is critical for substrate recognition. Furthermore, we show that this exosite acts as major determinant for inhibitor binding and, therefore, can be targeted for development of selective ADAMTS-5 inhibitors.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- TMPRSS2 inhibitor discovery facilitated through an in silico and biochemical screening platform 96%
- Fragment Screening and Structure-Guided Development of Heparanase Inhibitors Reveals Orthosteric and Allosteric Inhibition 94%
- AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity 93%
Similar papers in this journal
- A selective and rapid cell-permeable inhibitor of human caspase-3 96%
- Integrative x-ray structure and molecular modeling for the rationalization of procaspase-8 inhibitor potency and selectivity 95%
- Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor 94%
Similar papers in this journal
- Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. 94%
- Noninvasive optical detection of Granzyme B from natural killer cells using enzyme-activated fluorogenic probes 94%
- Conversion of an agonistic anti-TNFR2 biparatopic antibody into an antagonist by insertion of peptide linkers into the hinge region 93%
Similar papers in this journal
- Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands 95%
- HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2 94%
- A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3) 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.